The US Food and Drug Administration (FDA) has approved female-focused pharmaceutical company TherapeuticsMD’s TX-001HR (Bijuva) for the treatment of vasomotor symptoms, such as hot flushes, due to menopause.
In a trial carried out at Imperial College London, researchers showed that women who suffered seven or more hot flushes a day could reduce the number by as much as 73%, as well as reducing their severity and impact.